|
|
Restoret™
(MK-3000)
Mechanism of Action: MK-3000 is an investigational tri-specific antibody that acts as an agonist of the Wingless-related integration site (Wnt) signaling pathway.
Restoret was acquired as part of the acquisition of Eyebiotech Limited (EyeBio).
|
Ophthalmology |
|
Tri-specific antibody |
|
|
|
MK-1084
Mechanism of Action: MK-1084 is an investigational, oral selective KRAS G12C inhibitor.
MK-1084 is being developed through a collaboration with Taiho Pharmaceutical Co. Ltd and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd.
|
Oncology |
KRAS G12C-mutated non-small cell lung cancer
|
|
|
Small molecule |
|
|
|
raludotatug deruxtecan
(MK-5909)
Mechanism of Action: Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.
Raludotatug deruxtecan is being developed in collaboration with Daiichi Sankyo.
|
Oncology |
|
Antibody-drug conjugate |
|
|
|
MK-8527
Mechanism of Action: MK-8527 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) of HIV-1.
|
Antiviral |
|
Small molecule |
|
|
|
MK-6194
Mechanism of Action: MK-6194 is an investigational IL-2 mutein.
MK-6194 was acquired as part of the acquisition of Pandion Therapeutics
|
Immunology |
|
Therapeutic protein |
|
|
|
patritumab deruxtecan (MK-1022)
(MK-1022)
Mechanism of Action: Patritumab deruxtecan is an investigational antibody-drug conjugate that consists of a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.
Patritumab deruxtecan is being developed in collaboration with Daiichi Sankyo.
*In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working with Daiichi Sankyo to address FDA feedback.
|
Oncology |
Previously treated locally advanced or metastatic EGFR-mutated NSCLC
(HERTHENA-Lung01; NCT04619004)
|
Under review (US*) |
|
Non-small cell lung cancer (EU)
(HERTHENA-Lung02; NCT05338970)
|
|
|
Gastric cancer
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Melanoma
(HERTHENA-PanTumor01; NCT06172478)
|
|
|
Head and neck squamous cell cancer
|
|
|
Antibody-drug conjugate |
|
|
|
ifinatamab deruxtecan (MK-2400)
Mechanism of Action: Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload.
Ifinatamab deruxtecan is being developed in collaboration with Daiichi Sankyo.
|
Oncology |
Small cell lung cancer
(IDeate-Lung02; NCT06203210)
|
|
|
Bladder cancer
|
|
|
Colorectal cancer
|
|
|
Endometrial cancer
|
|
|
Head and neck squamous cell carcinoma
|
|
|
Antibody-drug conjugate |
|
|
|
tulisokibart
(MK-7240)
Mechanism of Action: Tulisokibart is an investigational humanized monoclonal antibody directed to tumor necrosis factor (TNF)-like ligand 1A (TL1A).
Tulisokibart was acquired as part of the acquisition of Prometheus Biosciences, Inc.
|
Immunology |
|
Monoclonal antibody |
|
|
|
bomedemstat
(MK-3543)
Mechanism of Action: Bomedemstat is an investigational lysine-specific demethylase-1 (LSD1) inhibitor.
Bomedemstat was acquired as part of the acquisition of Imago BioSciences, Inc.
|
Oncology |
Myeloproliferative disorders
|
|
|
Small molecule |
|
|
|
pembrolizumab + hyaluronidase subcutaneous
(MK-3475A)
Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
|
Oncology |
Non-small cell lung cancer
|
|
|
Cutaneous squamous cell carcinoma
|
|
|
Monoclonal antibody fixed-dose combination |
|
|
|
V181
Description: V181 is an investigational quadrivalent dengue vaccine.
|
Vaccines |
|
Vaccine |
|
|
|
opevesostat
(MK-5684)
Mechanism of Action: Opevesostat is an investigational oral inhibitor of cytochrome P450 11A1.
Opevesostat is being developed in collaboration with Orion.
|
Oncology |
|
Small molecule |
|
|
|
LENVIMA®
(MK-7902)
Mechanism of Action: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
LENVIMA is being developed in combination with KEYTRUDA.
LENVIMA is being developed in collaboration with Eisai.
|
Oncology |
Endometrial cancer
|
|
|
Esophageal cancer
|
|
|
Gastric cancer
|
|
|
Head and neck squamous cell cancer
|
|
|
Small molecule |
|
|
|
sacituzumab tirumotecan
(MK-2870)
Mechanism of Action: Sacituzumab tirumotecan is an investigational antibody-drug conjugate that consists of an antibody-targeting trophoblast cell-surface antigen 2 (TROP2) linked to a belotecan-derived payload.
Sacituzumab tirumotecan is being developed as monotherapy and/or in combination with KEYTRUDA.
Sacituzumab tirumotecan is being developed in collaboration with Sichuan Kelun-Biotech.
|
Oncology |
Breast cancer
|
|
|
Cervical cancer
(TroFuse-020; NCT06459180)
|
|
|
Endometrial cancer
|
|
|
Gastric cancer
(TroFuse-015; NCT06356311)
|
|
|
NSCLC
|
|
|
Biliary tract cancer
|
|
|
Colorectal cancer
|
|
|
Neoplasm malignant
|
|
|
Pancreatic cancer
|
|
|
Antibody-drug conjugate |
|
|
|
islatravir + lenacapavir
(MK-8591D)
Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor.
MK-8591D is on FDA partial clinical hold for higher doses than those used in current clinical trials.
Islatravir is being developed under an agreement with the Yamasa Corporation. The combination of islatravir and lenacapavir is being developed in a collaboration with Gilead Sciences, Inc.
|
Antiviral |
|
Small molecule fixed-dose combination |
|
|
|
vibostolimab + pembrolizumab
(MK-7684A)
Mechanism of Action: Vibostolimab is an investigational monoclonal antibody that binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits interactions with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
|
Oncology |
|
Monoclonal antibody fixed-dose combination |
|
|
|
MK-0616
Mechanism of Action: MK-0616 is an investigational inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9).
MK-0616 is being developed under an agreement with UCB Pharmaceuticals.
|
Cardiovascular |
|
Peptide |
|
|
|
WINREVAIR™
(MK-7962)
Mechanism of Action: Sotatercept is an investigational soluble activin receptor type IIA fusion protein that binds to activins and growth differentiation factors.
Sotatercept was acquired as part of the acquisition of Acceleron.
|
Cardiovascular |
Pulmonary arterial hypertension
|
Under review (EU) |
|
Pulmonary arterial hypertension
(SOTERIA; NCT04796337, ZENITH; NCT04896008, HYPERION; NCT04811092)
|
|
|
Pulmonary hypertension due to left heart disease
|
|
|
Therapeutic protein |
|
|
|
favezelimab + pembrolizumab
(MK-4280A)
Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
|
Oncology |
|
Monoclonal antibody fixed-dose combination |
|
|
|
WELIREG™
(MK-6482)
Mechanism of Action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes.
WELIREG is being developed as a monotherapy and/or in combination with KEYTRUDA.
WELIREG was acquired as part of the acquisition of Peloton Therapeutics, Inc.
|
Oncology |
|
Small molecule |
|
|
|
boserolimab
(MK-5890)
Mechanism of Action: Boserolimab is an investigational monoclonal antibody that binds and activates CD27.
Boserolimab is being developed in combination with KEYTRUDA.
Boserolimab is being developed under an agreement with Chinook Therapeutics.
|
Oncology |
|
Monoclonal antibody |
|
|
|
zilovertamab vedotin
(MK-2140)
Mechanism of Action: Zilovertamab vedotin is an investigational antibody-drug conjugate that consists of a ROR1-targeting antibody linked to monomethyl auristatin E (MMAE)-containing payload.
Zilovertamab vedotin was acquired as part of the acquisition of VelosBio.
|
Oncology |
|
Antibody-drug conjugate |
|
|
|
KEYTRUDA®
(MK-3475) **
Mechanism of Action: Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
**Select KEYTRUDA clinical trials are shown.
|
Oncology |
Resectable stage II, IIIA or IIIB non-small cell lung cancer
|
Under review (JPN) |
|
1L locally advanced or metastatic urothelial cancer
|
Under review (JPN) |
|
High-risk locally advanced cervical cancer
|
Under review (EU, JPN) |
|
Primary advanced or recurrent endometrial carcinoma
|
Under review (EU, JPN) |
|
1L unresectable advanced or metastatic malignant pleural mesothelioma
|
Under review (US, EU, JPN) |
|
Cutaneous squamous cell carcinoma (EU)
|
|
|
Hepatocellular carcinoma (EU)
|
|
|
Ovarian cancer
(KN-B96/ENGOT-ov65; NCT05116189)
|
|
|
Small cell lung cancer
|
|
|
Prostate cancer
|
|
|
Advanced solid tumors
|
|
|
Monoclonal antibody |
|
|
|
efinopegdutide
(MK-6024)
Mechanism of Action: Efinopegdutide is an investigational dual GLP-1/glucagon receptor agonist.
Efinopegdutide is being developed under an agreement with Hanmi Pharmaceutical.
|
Endocrinology |
Nonalcoholic Steatohepatitis
|
|
|
Peptide |
|
|
|
MK-2060
Mechanism of Action: MK-2060 is an investigational monoclonal antibody that inhibits the activation of Factor XI and activity of Factor XIA.
MK-2060 is being developed under an agreement with Adimab.
|
Cardiovascular |
|
Monoclonal antibody |
|
|
|
quavonlimab + pembrolizumab
(MK-1308A)
Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response.
Quavonlimab is being developed under an agreement with Akeso, Inc.
|
Oncology |
|
Monoclonal antibody fixed-dose combination |
|
|
|
MK-5475
Mechanism of Action: MK-5475 is an investigational stimulator of soluble Guanylate Cyclase (sGC).
|
Cardiovascular |
|
Small molecule |
|
|
|
LYNPARZA®
(MK-7339)
Mechanism of Action: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.
LYNPARZA is being developed as a monotherapy and/or in combination with KEYTRUDA.
LYNPARZA is being developed in collaboration with AstraZeneca.
|
Oncology |
|
Small molecule |
|
|
|
islatravir + MK-8507
(MK-8591B)
Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. MK-8507 is an investigational non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.
MK-8591B is on FDA clinical hold.
Islatravir is being developed under an agreement with the Yamasa Corporation.
|
Antiviral |
|
Small molecule fixed-dose combination |
|
|
|
V940
Mechanism of Action: V940 is an investigational mRNA-based individualized neoantigen therapy targeting tumor associated antigens expressed by a patient’s cancer cells.
V940 is being developed in combination with KEYTRUDA.
V940 is being developed in collaboration with Moderna.
|
Oncology |
|
Vaccine |
|
|
|
CAPVAXIVE™
(V116)
Description: V116 is a 21-valent pneumococcal conjugate vaccine.
|
Vaccines |
|
Vaccine |
|
|
|
LAGEVRIO™
(MK-4482)
Mechanism of Action: Molnupiravir is an investigational antiviral ribonucleoside prodrug of N-hydroxycytidine (NHC). NHC triphosphate is incorporated into viral RNA by viral RNA polymerase and results in an accumulation of errors in the viral genome leading to inhibition of replication.
LAGEVRIO is being developed under an agreement with Ridgeback Biotherapeutics LP. LAGEVRIO is available in the U.S. under Emergency Use Authorization.
|
Antiviral |
|
Small molecule |
|
|
|
islatravir + doravirine
(MK-8591A)
Mechanism of Action: Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor of HIV-1. Doravirine is a pyridinone non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.
MK-8591A is on FDA partial clinical hold for higher doses than those used in current clinical trials.
Islatravir is being developed under an agreement with the Yamasa Corporation.
|
Antiviral |
|
Small molecule fixed-dose combination |
|
|
|
favezelimab
(MK-4280)
Mechanism of Action: Favezelimab is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody designed to restore T cell effector function by preventing LAG-3 from binding to its primary ligand, major histocompatibility complex (MHC) class II molecules.
Favezelimab is being developed in combination with KEYTRUDA.
|
Oncology |
Non-small cell lung cancer
(KN-495/KeyImPaCT; NCT03516981)
|
|
|
Monoclonal antibody |
|
|
|
quavonlimab
(MK-1308)
Mechanism of Action: Quavonlimab is an investigational monoclonal antibody that binds to CTLA-4 and inhibits interaction with its ligands.
Quavonlimab is being developed in combination with KEYTRUDA.
Quavonlimab is being developed under an agreement with Akeso, Inc.
|
Oncology |
Non-small cell lung cancer
|
|
|
Monoclonal antibody |
|
|
|
nemtabrutinib
(MK-1026)
Mechanism of Action: Nemtabrutinib is an investigational reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is being studied for the suppression of oncogenic B-cell receptor signaling with activity against wild-type BTK and BTK pathway mutants.
Nemtabrutinib was acquired as part of the acquisition of ArQule, Inc.
|
Oncology |
|
Small molecule |
|
|
|
gefapixant
(MK-7264)
Mechanism of Action: Gefapixant is an investigational P2X3 receptor antagonist.
*In December 2023, FDA issued a CRL for the NDA for gefapixant. Merck is reviewing the feedback to determine next steps.
Gefapixant was acquired as part of the acquisition of Afferent Pharmaceuticals.
|
Respiratory |
|
Small molecule |
|
|
|
clesrovimab
(MK-1654)
Mechanism of Action: Clesrovimab is an investigational respiratory syncytial virus (RSV) fusion (F) glycoprotein neutralizing monoclonal antibody.
|
Respiratory |
Respiratory syncytial virus
|
|
|
Monoclonal antibody |
|
|
|
MK-8189
Mechanism of Action: MK-8189 is an investigational inhibitor of phosphodiesterase 10A (PDE10A).
MK-8189 is being developed under an agreement with Royalty Pharma. Phase 2b development costs are being co-funded.
|
Neuroscience |
|
Small molecule |